Semaglutide Age Approval
Semaglutide for type 2 diabetes (Ozempic) is approved for adults 18 years and older, while semaglutide for weight management (Wegovy) is approved for adults 18 years and older and adolescents 12 years and older with obesity. 1
Type 2 Diabetes Treatment (Ozempic)
The FDA label explicitly states that "safety and efficacy of OZEMPIC have not been established in pediatric patients (younger than 18 years)" 1. This means:
- Approved from age 18 years and above for type 2 diabetes management
- No pediatric indication currently exists for the diabetes formulation
- Clinical trials included adults across all age ranges, with substantial representation of older adults (23.6% were ≥65 years, 3.2% were ≥75 years) 1
Recent post-hoc analysis demonstrates that semaglutide shows particularly robust efficacy in young adults (≤40 years) with type 2 diabetes, with notable reductions in HbA1c and body weight compared to older age subgroups 2. This supports its use across the adult age spectrum once approved age is reached.
Weight Management (Wegovy)
For chronic weight management, semaglutide 2.4 mg was FDA approved in June 2021 for:
- Adults with BMI ≥30 kg/m² (obesity) 3
- Adults with BMI ≥27 kg/m² (overweight) plus at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia) 4, 3
- Adolescents aged 12 years and older with obesity (refer to Section 14 of guidelines for adolescent-specific dosing) 5
The 2025 ADA Standards of Care recommend prioritizing semaglutide or tirzepatide as preferred pharmacotherapy for adults with diabetes and overweight/obesity due to superior weight loss efficacy and cardiometabolic benefits 5.
Key Clinical Considerations
Important caveat: While approved from age 18 for diabetes, there is no upper age limit. The drug shows consistent safety and efficacy in geriatric populations, with no dose adjustment needed for older adults 1. Real-world evidence confirms effectiveness across all adult age groups, including those ≥75 years 6.
For weight management specifically, the adolescent indication (≥12 years) represents an important distinction from the diabetes indication, reflecting different regulatory pathways and clinical trial populations.